media – Page 531 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

30% of Practices Look toward EHR Replacement Options by 2021

Black Book found that one-third of practices with more than 11 clinicians are considering EHR replacement options within the next few years.
- Source: EHR Intelligence
- 653
- April 18, 2018
digital health EHR Market Views
NHS Digital’s sharing of non-clinical patient data branded “inappropriate”

NHS Digital’s sharing of non-clinical patient information with the Home Office has been branded “entirely inappropriate” by MPs, who say they are concerned about the body’s ability to act as a reliable steward of the data.
- Source: DigitalHealth
- 647
- April 18, 2018
Company Insights digital health NHS
Supercharged sector as the Federal Government backs $200 million Digital Health CRC

In a major boost to Australia’s digital health sector, the Federal Government has announced a $55 million cash injection to launch the new Digital Health Cooperative Research Centre and its R&D consortium of more than 60 technology companies, universities, health networks and research institutes.
- Source: Healthcare IT
- 502
- April 18, 2018
digital health Market Views
Drugs for Neglected Diseases initiative and Pharco Pharmaceuticals to test affordable hepatitis C regimen with support of Malaysian and Thai governments

Potentially pan-genotypic combination of ravidasvir and sofosbuvir to be tested in Malaysia and Thailand with target price of under $300
- Source: dndi
- 664
- April 17, 2018
Clinical Trials hepatitis C
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) + Yervoy® (ipilimumab) Combination as First-Line Treatment

Bristol-Myers Squibb Company (NYSE: BMY) today announced that Opdivo (nivolumab) 3 mg/kg plus Yervoy (ipilimumab) 1 mg/kg (injections for intravenous use) was approved by the U.S. Food and Drug Administration (FDA) as the first Immuno-Oncology combination therapy for previously untreated patients with intermediate- and poor-risk advanced renal cell carcinoma (RCC).
- Source: news.bms
- 902
- April 17, 2018
New Approvals Opdivo RCC Yervoy
Updated Overall Survival Data for LYNPARZA® (olaparib) in gBRCA-Mutated HER2-Negative Metastatic Breast Cancer Presented at AACR

AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) today presented data from the Phase III OlympiAD trial, showing the final overall survival (OS) results for LYNPARZA®(olaparib) in metastatic breast cancer at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, April 14-18, 2018.
- Source: businesswire
- 879
- April 17, 2018
AstraZeneca breast cancer Clinical Trials Merk
Shire Announces Sale of Oncology Business to Servier for $2.4 Billion

Sale of Oncology business unlocks embedded value within Shire`s portfolio and sharpens focus on core areas reinforcing our leadership in rare diseases
- Source: finance.yahoo
- 657
- April 17, 2018
Company Insights oncology rare diseases
New blood pressure guidelines could put lives at risk, say experts

A new report in JAMA Internal Medicine by University of Sydney and Bond University scholars weighs the risks and benefits of a recent change to blood pressure guidelines in the US.
- Source: MedicalXpress
- 561
- April 17, 2018
blood pressure Policies
Telemedicine robot enables physician consultations in multiple locations

Using the device, called a Beam, Miramont Family Medicine now sees more patients than ever – enabling physicians to be in more than one of its four locations at the same time.
- Source: HealthIT News
- 547
- April 17, 2018
Company Insights mHealth Telemedicine
Sword Health lands $4.6M for digital physical therapy

Digital physiotherapy company Sword Health has brought in $4.6 million in a seed funding round led by Green Innovation, Vesalius Biocapital III, and other unnamed US and European investors.
- Source: MobiHealthNews
- 840
- April 17, 2018
AI Company Insights digital health

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.